Society of Gynecologic Oncology (SGO)

The Society of Gynecologic Oncology (SGO), headquartered in Chicago, Illinois, is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers, affecting the uterus, fallopian tubes, ovaries, cervix, vagina, and vulva. As a 501(c)(6) organization, the SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations.
Study Says Black Women Disproportionately Suffer Throughout Cancer Treatment
SGO 2020
Patient-reported outcomes from nearly 2000 women with gynecologic cancers revealed that black women have more suffering, less support, and worse health than white women. Read More ›
Substantial Benefit with Addition of Olaparib to Bevacizumab Maintenance in Newly Diagnosed Advanced Ovarian Cancer
SGO 2020
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across all important subgroups. Read More ›
Routine Prospective Collection of Patient-Reported Outcomes Can Be Adopted Widely
SGO 2020
Initial findings from a large-scale, patient-reported outcomes program reveal that patients with gynecologic malignancy do not report worse quality of life after surgery. Read More ›
In Advanced Ovarian Cancer, Treatment with Niraparib Not Associated with Worse Quality of Life
SGO 2020
New research shows that treatment with niraparib does not negatively impact quality of life in patients with ovarian cancer. Read More ›
Niraparib Improves Progression-Free Survival in Advanced Ovarian Cancer, Regardless of Subgroup
SGO 2020
In an exploratory analysis of a phase 3 study, niraparib improved progression-free survival in patients with advanced ovarian cancer across all important subgroups. Read More ›
Data Suggest Longer Time to First Subsequent Therapy in Patients with Advanced Ovarian Cancer on Niraparib
SGO 2020
Preliminary data on time to first subsequent therapy and second progression-free survival support clinical benefit of niraparib over placebo. Read More ›

Page 2 of 2

  • 1
  • 2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Oncology Practice Management

Learn more about our family of publications.

View Our Publications

© Amplity Health. All Rights Reserved. Privacy Policy